Which dogs with appendicular osteosarcoma benefit most from chemotherapy after surgery? Results from an individual patient data meta-analysis

Preventive Veterinary Medicine
A F SchmidtM Nielen

Abstract

Osteosarcoma (OS) is a malignant tumor of mesenchymal origin that produces osteoid. Given that the prognosis can vary considerably between dogs, we aimed to explore whether treatment could be tailored towards patient subgroups, characterized by their predicted risk of mortality. For the current study, a subset of five nonrandomized studies (400 subjects of whom 88 were dead at 5 months follow-up) was used from a previously published 20 study individual patient data meta-analysis. Missing data was dependent on observed variables and was imputed to correct for this dependency. Based on a previously published multivariable prognostic model, the 5-month mortality risk was predicted. Subsequently, in surgically treated dogs, using a logistic regression model with a random intercept for a study indicator, we explored whether chemotherapy effectiveness depended on predicted 5-month mortality risk. After adjustment for potential confounders the main effect of any chemotherapy was 0.48 (odds ratio) (95%CI 0.30; 0.78). Testing for chemotherapy by predicted 5-month mortality risk interaction revealed that the effects of any chemotherapy decreased with increasing predicted risk; interaction OR 3.41 (1.07; 10.84). Results from individually ...Continue Reading

References

Jul 1, 1991·Journal of Veterinary Internal Medicine·R C StrawW B Morrison
Jan 21, 1995·BMJ : British Medical Journal·J M Bland, D G Altman
Jan 1, 1996·The Veterinary Clinics of North America. Small Animal Practice·R C Straw, S J Withrow
Jan 1, 1997·Journal of the American Animal Hospital Association·D M Cooley, D J Waters
Aug 6, 1998·The Veterinary Journal·G RuL T Glickman
Oct 8, 1999·Journal of Clinical Epidemiology·E W SteyerbergJ D Habbema
Sep 30, 2000·Journal of Veterinary Internal Medicine·R ChunE G MacEwen
Jan 16, 2002·American Journal of Epidemiology·Miguel A HernánAllen A Mitchell
May 15, 2002·Veterinary Pathology·J KirpensteijnE Teske
Apr 15, 2005·Monash Bioethics Review·Kim Little
Nov 4, 2005·Journal of the American Animal Hospital Association·Ruthanne ChunNicole M Azene
Feb 27, 2007·BMJ : British Medical Journal·Douglas G Altman, J Martin Bland
Dec 20, 2007·Epidemiology·Patrick G ArbogastWayne A Ray
Sep 3, 2008·Journal of Veterinary Internal Medicine·K KowS E Lana
Sep 16, 2010·Journal of Veterinary Internal Medicine·J L SottnikS W Dow
Oct 29, 2011·Journal of Clinical Epidemiology·Ewout W SteyerbergFrank E Harrell
May 17, 2012·BMC Veterinary Research·Ilse BoermanJolle Kirpensteijn
Jan 16, 2014·Circulation. Cardiovascular Quality and Outcomes·James F BurkeDavid M Kent
Jul 2, 2014·Journal of the American Veterinary Medical Association·Pierre M AmsellemJames P Farese
Mar 31, 2015·Journal of Clinical Epidemiology·David van KlaverenEwout W Steyerberg

❮ Previous
Next ❯

Citations

Feb 16, 2016·Pharmacoepidemiology and Drug Safety·A F SchmidtA W Hoes
Nov 21, 2017·Journal of the American Veterinary Medical Association·Hailey TurnerLaura E Selmic
Jul 10, 2019·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Tanya WrightDorothee Bienzle
Jun 21, 2019·Therapeutic Advances in Medical Oncology·Federica RiccardoFederica Cavallo
Oct 29, 2020·Journal of the American Animal Hospital Association·Marije RisseladaB Duncan X Lascelles
Jan 16, 2021·The Veterinary Clinics of North America. Small Animal Practice·Janis Lapsley, Laura E Selmic

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Polyendocrinopathies

Autoimmune polyendocrinopathies, also called polyglandular autoimmune syndromes (PGASs), or polyendocrine autoimmune syndromes(PASs), are a heterogeneous group of rare diseases characterized by autoimmune activity against more than one endocrine organ, although non-endocrine organs can be affected. Discover the latest research on autoimmune polyendocrinopathies here.

Autoimmune Polyendocrine Syndromes

This feed focuses on a rare genetic condition called Autoimmune Polyendocrine Syndromes, which are characterized by autoantibodies against multiple endocrine organs. This can lead to Type I Diabetes.